bit.bio selected to join the ‘Future Fifty’ 2024 cohort as one of the UK’s most exciting technology companies.
bit.bio selected to join the ‘Future Fifty’ 2024 cohort as one of the UK’s most exciting technology companies.
bit.bio selected to join the ‘Future Fifty’ 2024 cohort as one of the UK’s most exciting technology companies.
bit.bio selected to join the ‘Future Fifty’ 2024 cohort as one of the UK’s most exciting technology companies.
bit.bio announce first project in multi-year collaboration agreement with The Michael J. Fox Foundation to generate products for r...
bit.bio launches panel of 16 neurodegenerative disease models for research and drug discovery in Alzheimer’s and Parkinson’s disea...
Ginkgo Technology Network brings together over 25 partners across an array of capabilities including AI, genetic medicines, biolog...
Team will present posters including 2 on ioCRISPR-Ready Cells & host an expert panel discussion on the important role of functiona...
Product will provide robust, standardised tool for study and screening of potential treatments for motor neuron diseases.
Minister Griffith cut the ribbon to officially open bit.bio’s manufacturing and automation labs for the consistent and scalable pr...
King's College London & bit.bio collaborate to develop multi-cell models of the human brain with optimised open-source protocols f...
Mark Kotter wins in two categories, Equity-Backed Entrepreneur of the Year and Purpose Entrepreneur of the Year, at the Great Brit...